Deep-vein thrombosis of the lower limbs: Diagnosis and management

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 12, Issue 3, 1999, Pages 533-554

  Prandoni, Paolo ^a   Mannucci, Pier Mannuccio ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Deep vein thrombosis; Low molecular weight heparin; Oral anticoagulants; Thrombophilic state; Venous thromboembolism

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; D DIMER; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

AGING; ANXIETY; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIAGNOSTIC APPROACH ROUTE; DISEASE COURSE; FATALITY; HUMAN; IMPEDANCE PLETHYSMOGRAPHY; LEG PHLEBOGRAPHY; LUNG EMBOLISM; MORBIDITY; NONHUMAN; PATIENT CARE; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; REVIEW; THROMBECTOMY; THROMBOCYTOPENIA; ULTRASOUND; VENA CAVA FILTER;

EID: 0033497940     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0039     Document Type: Article

References (107)

1. Gillum R F. Pulmonary embolism and thrombophlebitis in the United States, 1970-1985. American Heart Journal. 114:1987;1262-1264.
2. Anderson F A, Wheeler H B, Goldberg R J. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and PE. The Worcester DVT study. Archives of Internal Medicine. 151:1991;933-938.
3. Weinman E E, Salzman E W. Deep-vein thrombosis. New England Journal of Medicine. 331:1994;1630-1641.
4. Nordström M, Lindbläd B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. Journal of Internal Medicine. 232:1992;155-160.
5. Hansson P O, Werlin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. Archives of Internal Medicine. 157:1997;1665-1670.
6. Cohen A T, Edmondson R A, Phillips M J. The changing pattern of venous thromboembolic disease. Haemostasis. 26:1996;65-71.
7. Lilienfeld D E, Godbold J H, Burke G L. Hospitalization and case fatality for pulmonary embolism in the twin cities: 1979-1984. American Heart Journal. 120:1990;392-395.
8. Salzman E W, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. Colman R W, Hirsh J, Marder V, Salzman E W. Thrombosis and Haemostasis. Basic Principles and Clinical Practice. 1993;1275-1296 JB Lippincott, Philadelphia.
9. Carter C J. Epidemiology of venous thromboembolism. Hull R, Pineo G F. Disorders of Thrombosis. 1996;159-174 W. B. Saunders, Philadelphia.
10. Rosendaal F R. Risk factors for venous thrombosis: prevalence, risk, and interaction. Seminars in Haematology. 34:1997;171-187.
11. De Stefano V, Finazzi G, Mannucci P M. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood. 87:1996;3531-3544.
12. Hirsh J, Prins M H, Samama M. Approach to the thrombophilic patient for hemostasis and thrombosis: basic principles and clinical practice. Colman R W, Hirsh J, Marder V J, Salzman E W. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 1993;1543-1561 JB Lippincott, Philadelphia.
13. Lane D A, Mannucci P M, Bauer K A. Inherited thrombophilia: part 1. Thrombosis and Haemostasis. 7:1996;651-662.
14. Kravitz E, Karino T. Pathophysiology of deep vein thrombosis. Leclerc J R. Venous Thromboembolic Disorders. 1991;54-64 Lea & Febiger, Philadelphia.
15. Fraser R S. Pathologic characteristics of venous thromboembolism. Leclerc J R. Venous Thromboembolic Disorders. 1991;37-53 Lea & Febiger, Philadelphia.
16. Colman N C. Pathophysiology of pulmonary embolism. Leclerc J R. Venous Thromboembolic Disorders. 1991;65-73 Lea & Febiger, Philadelphia.
17. Leclerc J R. Natural history of venous thromboembolism. Leclerc J R. Venous Thromboembolic Disorders. 1991;166-175 Lea & Febiger, Philadelphia.
18. Cogo A, Lensing A WA, Prandoni P, Hirsh J. Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. Archives of Internal Medicine. 153:1993;2777-2780.
19. Bauer J. A venographic study of thromboembolism problems. Acta Chirurgica Scandinavica. 84:1940;1-7.
20. Lensing A WA, Hirsh J, Büller H R. Diagnosis of venous thrombosis. Colman R W, Hirsh J, Marder V J, Salzman E W. Haemostasis and Thrombosis: Basic Principles and Clinical Practice. 1993;1297-1321 JB Lippincott, Philadelphia.
21. Büller H R, Lensing A WA, Hirsh J, ten Cate J W. Deep venous thrombosis: new noninvasive tests. Thrombosis and Haemostasis. 66:1991;133-139.
22. Cranley J J, Canos A J, Sull W J. The diagnosis of deep vein thrombosis: fallibility of clinical signs and symptoms. Archives of Surgery. 111:1976;34-36.
23. Lensing A WA, Prandoni P, Brandjes D. Detection of deep-vein thrombosis by real-time B-mode ultrasonography. New England Journal of Medicine. 320:1989;342-345.
24. Haeger K. Problems of acute deep vein thrombosis: I. The interpretation of signs and symptoms. Angiology. 20:1969;219-223.
25. Hirsh J, Hull R D, Raskob G E. Clinical features and diagnosis of venous thrombosis. Journal of the American College of Cardiology. 8:1986;114B-127B.
26. Forbes C D, Lowe D O. Clinical diagnosis of venous thrombosis. Hirsh J. Venous Thrombosis and Pulmonary Embolism. 1987;9-19 Churchill Livingstone, Edinburgh.
27. Wells P S, Hirsh J, Anderson D R. A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. Journal of Internal Medicine. 243:1998;15-23.
28. Hull R D, Hirsh J, Sackett D L. Clinical validity of a negative venogram in patients with clinically suspected venous thrombosis. Circulation. 64:1981;622-625.
29. Hull R D, Hirsh J, Carter C J. Diagnostic efficacy of plethysmography for clinically suspected deep vein thrombosis: a randomized trial. Annals of Internal Medicine. 102:1985;21-28.
30. Heijboer H, Büller H R, Lensing A WA. A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. New England Journal of Medicine. 329:1993;1365-1369.
31. Huisman M V, Büller H R, ten Cate J W, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis. The Amsterdam general practitioner study. New England Journal of Medicine. 314:1986;823-828.
32. Huisman M V, Büller H R, ten Cate J W. Management of clinically suspected acute venous thrombosis in outpatients with serial impedance plethysmography in a community hospital setting. Archives of Internal Medicine. 149:1989;511-513.
33. Prandoni P, Lensing A WA, Büller H R. Failure of computerized impedance plethysmography in the management of clinically suspected deep-vein thrombosis. Thrombosis and Haemostasis. 65:1991;233-236.
34. Kraajenhagen R A, Lensing A WA, Lijmer J G. Diagnostic strategies for the management of patients with clinically suspected deep-vein thrombosis. Current Opinion in Pulmonary Medicine. 3:1997;268-274.
35. Cogo A, Lensing A WA, Prandoni P. Comparison of real-time B mode ultrasonography and Doppler ultrasound with contrast venography in the diagnosis of venous thrombosis in symptomatic outpatients. Thrombosis and Haemostasis. 70:1993;404-407.
36. Cogo A, Lensing A WA, Koopman M MW. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. British Medical Journal. 316:1998;17-20.
37. Birdwell B G, Raskob G E, Whitsett T L. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Annals of Internal Medicine. 128:1998;1-7.
38. Sluzewski M, Koopman M M, Schuur K H. Influence of negative ultrasound findings on the management of in- and outpatients with suspected deep-vein thrombosis. European Journal of Radiology. 13:1991;174-177.
39. Kraajenhagen R A, Koopman M MV, Bernardi E. Simplification of the diagnostic management of outpatients with symptomatic deep vein thrombosis with D-dimer measurements. Thrombosis and Haemostasis. 78:1997;PD-652.
40. Bernardi E, Prandoni P, Lensing A WA. D-Dimer testing as an adjunct to ultrasonography in patients with clinically suspected deep vein thrombosis: prospective cohort study. British Medical Journal. 317:1998;1037-1040.
41. Wells P S, Anderson D R, Bormanis J. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 350:1997;1795-1798.
42. Wells P S, Anderson D R, Bormanis J. Application of a diagnostic clinical model for the management of hospitalized patients with suspected deep-vein thrombosis. Thrombosis and Haemostasis. 81:1999;493-497.
43. Perrier A, Desmarais S, Miron M J. Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet. 353:1999;190-195.
44. Hull R D, Carter C, Jay R. The diagnosis of acute recurrent deep-vein thrombosis: a diagnostic challenge. Circulation. 67:1983;901-905.
45. Huisman M V, Büller H R, ten Cate J W. Utility of impedance plethysmography in the diagnosis of recurrent deep-vein thrombosis. Archives of Internal Medicine. 148:1988;681-685.
46. Heijboer H, Jongbloets L MM, Büller H R. Clinical utility of real-time compression ultrasonography for diagnostic management of patients with recurrent venous thrombosis. Acta Radiologica. 33:1992;297-300.
47. Prandoni P, Cogo A, Bernardi E. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation. 88:1993;1730-1735.
48. 125I-fibrinogen leg scanning: reassessment of its role for the diagnosis of venous thrombosis in post-operative patients. Thrombosis and Haemostasis. 69:1993;2-7.
49. Jongbloets L MM, Lensing A WA, Koopman M MW. Limitations of compression ultrasound for the detection of symptomless postoperative deep vein thrombosis. Lancet. 343:1994;1142-1144.
50. Lensing A WA, Doris C I, McGrath F P. A comparison of compression ultrasound with color Doppler ultrasound for the diagnosis of symptomless postoperative deep vein thrombosis. Archives of Internal Medicine. 157:1997;765-768.
51. Wells P S, Lensing A WA, Davidson B L. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopaedic surgery. Annals of Internal Medicine. 122:1995;47-53.
52. Davidson B L, Elliott C G, Lensing A WA. Low accuracy of color-Doppler ultrasound in the detection of proximal leg vein thrombosis in asymptomatic high-risk patients. Annals of Internal Medicine. 117:1992;735-738.
53. Hirsh J. Heparin. New England Journal of Medicine. 324:1991;1565-1574.
54. Hirsh J, Warkentin T E, Raschke R. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 114:1998;489-510.
55. Brandjes D PM, Heijboer H, Büller H R. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. New England Journal of Medicine. 327:1992;1485-1489.
56. Raschke R A, Reilly B M, Guidry J R. The weight-based heparin dosing normogram compared with a 'standard care' normogram. A randomized controlled trial. Annals of Internal Medicine. 119:1993;874-881.
57. White R H, Zhou H, Mungall D. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements. Archives of Internal Medicine. 157:1997;2468-2472.
58. Hull R D, Raskob G E, Hirsh J. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. New England Journal of Medicine. 315:1986;1109-1114.
59. Cruickshank M K, Levine M N, Hirsh J. A standard heparin nomogram for the management of heparin therapy. Archives of Internal Medicine. 151:1991;333-337.
60. Raschke R A, Gollihare B, Peirce J C. The effectiveness of implementing the weight-based heparin normogram as a practice guideline. Archives of Internal Medicine. 156:1996;1645-1649.
61. Anand S, Ginsberg J S, Kearon C. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Archives of Internal Medicine. 156:1996;1677-1681.
62. Hull R D, Raskob G E, Brant R F. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. Archives of Internal Medicine. 157:1997;2317-2321.
63. Hull R D, Raskob G E, Brant R F. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Archives of Internal Medicine. 157:1997;2562-2568.
64. Levine M N, Hirsh J, Gent M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Archives of Internal Medicine. 154:1994;49-56.
65. Baker B A, Adelman M D, Smith P A, Osborn J C. Inability of the activated partial thromboplastin time to predict heparin levels. Archives of Internal Medicine. 157:1997;2475-2479.
66. Gallus A S, Jackaman J, Tiillett J. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 2:1986;1293-1296.
67. Hull R D, Raskob G E, Rosenbloom D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. New England Journal of Medicine. 322:1990;1260-1264.
68. Hommes D W, Bura A, Mazzolai L. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Annals of Internal Medicine. 116:1992;279-284.
69. Prandoni P, Bagatella P, Bernardi E. Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis. Annals of Internal Medicine. 129:1998;299-302.
70. Reilly B M, Raschke R, Srinivas S, Nieman T. Intravenous heparin dosing: patterns and variations in internists' practices. Journal of General Internal Medicine. 8:1993;536-542.
71. Cambell N RC, Hull R D, Brant R. Aging and heparin-related bleeding. Archives of Internal Medicine. 156:1996;857-860.
72. Juergens C P, Semsarian C, Keech A C. Hemorrhagic complications of intravenous heparin use. American Journal of Cardiology. 80:1997;150-154.
73. Nand S, Wong W, Yuen B. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. American Journal of Hematology. 56:1997;12-16.
74. Hirsh J, Levine M N. Low molecular weight heparin. Blood. 79:1992;1-17.
75. Weitz J I. Low-molecular-weight heparins. New England Journal of Medicine. 337:1997;688-698.
76. Dolovich L, Ginsberg J S. Low molecular weight heparins in the treatment of venous thromboembolism. An updated meta-analysis. Vessels. 3:1997;4-11.
77. Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients with low-molecular-weight heparin or unfractionated heparin. New England Journal of Medicine. 332:1995;1330-1335.
78. Lensing A WA, Prins M H, Davidson B L, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparin: a meta-analysis. Archives of Internal Medicine. 155:1995;601-607.
79. Siragusa S, Cosmi B, Piovella F. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. American Journal of Medicine. 100:1996;269-277.
80. Koopman M MW, Prandoni P, Piovella F. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. New England Journal of Medicine. 334:1996;682-687.
81. Levine M, Gent M, Hirsh J. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine. 334:1996;677-681.
82. van den Belt A GM, Bossuyt P MM, Prins M H. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis. An economic evaluation. Thrombosis and Haemostasis. 79:1997;259-263.
83. New England Journal of Medicine. 337:1997;657-662.
84. Simonneau G, Sors H, Charbonnier B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. New England Journal of Medicine. 337:1997;663-669.
85. Wells P S, Kovacs M J, Bormanis J. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Archives of Internal Medicine. 158:1998;1809-1812.
86. Prandoni P. Unfractionated and low-molecular-weight heparin for the initial treatment of acute venous thromboembolism. Haemostasis. 28:1998;85-90.
87. Piccioli A, Prandoni P, Ewenstein B M, Goldhaber S Z. Cancer and venous thromboembolism. American Heart Journal. 132:1996;850-855.
88. Greenfield L J, Michna B A. Twelve-year clinical experience with the Greenfield vena cava filter. Surgery. 104:1988;706-712.
89. Decousus H, Leizorovics A, Parent F. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. New England Journal of Medicine. 338:1998;409-415.
90. Mahorner H, Castelberry J W, Coleman W D. Attempts to restore function in major veins which are the site of massive thrombosis. Annals of Surgery. 146:1957;510-517.
91. Karp R B, Wylie E J. Recurrent thrombosis after iliofemoral venous thrombectomy. Surgical Forum. 17:1966;147-153.
92. Lensing A WA, Hirsh J. Rationale and results of thrombolytic therapy for deep vein thrombosis. Bernstein E F. Vascular Diagnosis. 1993;875-879 Mosby, St Louis.
93. Goldhaber S Z, Buring J E, Lipnick R J, Hennekens C H. Pooled analysis of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. American Journal of Medicine. 76:1984;393-398.
94. Hull R, Raskob G E, Hirsh J, Sackett D L. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. Journal of the American Medical Association. 252:1984;235-239.
95. Lopaciuk S, Bielska-Falda H, Noszczyk W. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thrombosis and Haemostasis. 81:1999;26-31.
96. Monreal M, Lafoz E, Olive A. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thrombosis and Haemostasis. 71:1994;7-11.
97. Pini M, Aiello S, Manotti C. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thrombosis and Haemostasis. 72:1994;191-197.
98. Prandoni P, Lensing A WA, Cogo A. The long-term clinical course of acute deep venous thrombosis. Annals of Internal Medicine. 125:1996;1-7.
99. Simioni P, Prandoni P, Lensing A WA. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). New England Journal of Medicine. 336:1997;399-403.
100. Schulman S, Rhedin A S, Lindmarker P. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. New England Journal of Medicine. 332:1995;1661-1665.
101. Kearon C, Gent M, Hirsh J. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. New England Journal of Medicine. 340:1999;901-907.
102. Simioni, P, Prandoni, P, Lensing, A, WA, Risk of subsequent venous thromboembolic complications in carriers of the prothrombin or factor V gene mutation with a first episode of deep-vein thrombosis.
103. Schulman S, Granqvist S, Holmstrom M. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. New England Journal of Medicine. 336:1997;393-398.
104. Levine M N, Raskob G E, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 114:1998;511-523.
105. Palareti G, Leali N, Coccheri S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 348:1996;423-428.
106. Prandoni P, Lensing A WA, Bagatella P. Low rate of warfarin-related major bleeding in patients with recurrent venous thromboembolism. Thrombosis and Haemostasis. 82:1999;158-159.
107. Lensing A WA, Prandoni P, Prins H R, Büller H R. Deep-vein thrombosis. Lancet. 353:1999;479-485.